Regeneron Pharmaceuticals, Inc.
Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)
Last updated:
Abstract:
The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R.alpha.) inhibitor such as an anti-IL-4R.alpha. antibody.
Status:
Grant
Type:
Utility
Filling date:
24 Jun 2020
Issue date:
23 Aug 2022